Trial intelligence / Profile preview

R-COMP-14 as first-line therapy for aggressive non-Hodgkin lymphoma

2004-001199-37Phase 4Active

Sponsor: (GOTEL) Grupo OncolÃ³gico para el tratamiento y estudio de los linfomas
Start: Apr 2010
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of rituximab, cyclophosphamide, vincristine, pegylated liposomal doxorubicin and prednisone in non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL), sponsored by (GOTEL) Grupo OncolÃ³gico para el tratamiento y estudio de los linfomas. Primary endpoint: overall response rate. Started Apr 2010; status: active.

Drugs

rituximabcyclophosphamidevincristinepegylated liposomal doxorubicinprednisone

Conditions

non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)

Beyond the preview

Go deeper on 2004-001199-37.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-001199-37.